PapanasNSymeonidisGMaltezosE. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004;15(8):475–478.
2.
JagroopAMikhailidisDP. Platelets and diabetes: a complex association. Platelets. 2015;26(3):267–268.
3.
PapanasNMavridisGKaravageliESymeonidisGMaltezosE. Peripheral neuropathy is associated with increased mean platelet volume in type 2 diabetic patients. Platelets. 2005;16(8):498–499.
4.
GasparyanAYAyvazyanLMikhailidisDPKitasGD. Mean platelet volume: a link between thrombosis and inflammation?Curr Pharm Des. 2011;17(1):47–58.
5.
VarolEAksoyFBasHAAriHOzaydinM. Mean platelet volume is elevated in patients with low high-density lipoprotein cholesterol. Angiology. 2014;65(8):733–736.
6.
TsiaraSElisafMJagroopIAMikhailidisDP. Platelets as predictors of vascular risk: is there a practical index of platelet activity?Clin Appl Thromb Hemost. 2003;9(3):177–190.
7.
NenaEPapanasNSteiropoulosP. Mean platelet volume and platelet distribution width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity?Platelets. 2012;23(6):447–454.
8.
SteiropoulosPPapanasNNenaE. Mean platelet volume and platelet distribution width in patients with chronic obstructive pulmonary disease: the role of comorbidities. Angiology. 2013; 64(7):535–539.
9.
AcikgozNKarincaogluYErmisN. Increased mean platelet volume in Behçet’s disease with thrombotic tendency. Tohoku J Exp Med. 2010;221(2):119–123.
10.
SahinDYGürMElbasanZ. Mean platelet volume and extent and complexity of coronary artery disease in diabetic and nondiabetic patients with ST elevation myocardial infarction. Angiology. 2013;64(7):505–511.
11.
MuratSNDuranMKalayN. Relation between mean platelet volume and severity of atherosclerosis in patients with acute coronary syndromes. Angiology. 2013;64(2):131–136.
12.
HanJYChoiDHChoiSW. Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2013;24(5):401–406.
13.
PapanasNMikhailidisDP. Mean platelet volume: a predictor of mortality in diabetic and non-diabetic patients with STEMI?J Diabetes Complications. 2014;28(5):581–582.
14.
MikhailidisDPAthyrosVG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol. 2014;11(2):72–74.
15.
AgouridisAPFilippatosTDKatsikiN. Current lipid-modifying agents. Expert Opin Pharmacother. 2015;16(7):1117–1118.
16.
HuhleGAbletshauserCMayerNWeidingerGHarenbergJHeeneDL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res. 1999;95(5):229–234.
17.
SchrorK. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents. Eicosanoids. 1990;3(2):67–73.
18.
PawelczykMChmielewskiHKaczorowskaBPrzybyłaMBajZ. The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke. Arch Med Sci. 2015;11(1):115–121.
19.
SextonTRWallaceELMacaulayTE. The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome. J Am Coll Cardiol. 2015;65(3):306–307.
20.
SextonTRWallaceELMacaulayTE. The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis. 2015;39(2):186–195.
21.
DuHHuHZhengHHaoJYangJCuiW. Effects of peroxisome proliferator-activated receptor γ in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases. Thromb Res. 2014;134(1):111–120.
22.
VioliFCarnevaleRPastoriDPignatelliP. Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. Trends Cardiovasc Med. 2014;24(4):142–148.
23.
CobanEAfacanB. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets. 2008;19(2):111–114.
24.
SivriNTekinGYaltaKAksoyYSenenKYetkinE. Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiol Pol. 2013;71(10):1042–1047.
25.
KuceraMBalazDKruzliakP. The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators-A pilot study. Clin Biochem. 2015;48(9):557–561.
26.
AkinFAyçaBKöseN. Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia. Angiology. 2013;64(8):621–625.
27.
BroijersenAErikssonMLarssonPT. Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia. Eur J Clin Invest. 1994;24(7):488–498.
28.
AkyüzAAkkoyunDÇDeğirmenciHOranM. Rosuvastatin decreases mean platelet volume in patients with diabetes mellitus[published online on May 5, 2015]. Angiology. 2015. doi: 10.1177/0003319715584725.
29.
CrawfordVLMcNerlanSEStoutRW. Seasonal changes in platelets, fibrinogen and factor VII in elderly people. Age Ageing. 2003;32(6):661–665.
30.
MikhailidisDPBarradasMAJeremyJYDandonaP. Effect of alpha a-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32(2):147–149.
31.
KeiAElisafM. Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia. Arch Med Sci. 2014;10(3):439–444.
32.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol. 2012;6(1):93.
33.
KargiotisKKatsikiNAthyrosVG. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol. 2014;12(3):505–511.
34.
EliotTS.Collected Poems 1909-1962. London: Faber and Faber; 1986: 203.
